Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RGNX Stock Forecast 2026-2027
$7.07
Current Price
$365.50M
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RGNX Price Targets
+607.2%
To High Target of $50.00
+168.7%
To Median Target of $19.00
+41.4%
To Low Target of $10.00
RGNX Price Momentum
+11.5%
1 Week Change
+23.6%
1 Month Change
-22.8%
1 Year Change
-50.9%
Year-to-Date Change
-56.3%
From 52W High of $16.19
+29.6%
From 52W Low of $5.46
📊 TOP ANALYST CALLS
Did RGNX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if REGENXBIO is one of their latest high-conviction picks.
Latest RGNX Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, RGNX has a bullish consensus with a median price target of $19.00 (ranging from $10.00 to $50.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $7.07, the median forecast implies a 168.7% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RGNX Analyst Ratings
10
Buy
1
Hold
0
Sell
RGNX Price Target Range
Low
$10.00
Average
$19.00
High
$50.00
Current: $7.07
Latest RGNX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RGNX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 5, 2026 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $26.00 |
| May 15, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| May 15, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Mar 9, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 6, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Feb 10, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 10, 2026 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Feb 10, 2026 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Feb 10, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Jan 29, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 19, 2025 | Stifel | Buy | Maintains | $N/A | |
| Dec 15, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| Nov 20, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 7, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Oct 7, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 8, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 8, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 8, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Aug 8, 2025 | Barclays | Overweight | Maintains | $N/A |
Regenxbio Inc. (RGNX) Competitors
The following stocks are similar to REGENXBIO based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Regenxbio Inc. (RGNX) Financial Data
Regenxbio Inc. has a market capitalization of $365.50M with a P/E ratio of -1.9x. The company generates $87.82M in trailing twelve-month revenue with a 88.1% profit margin.
Revenue growth is -92.8% quarter-over-quarter, while maintaining an operating margin of -1,304.0% and return on equity of -196.4%.
Valuation Metrics
Market Cap
$365.50M
Enterprise Value
$463.41M
P/E Ratio
-1.9x
PEG Ratio
0.0x
Price/Sales
4.2x
Growth & Margins
Revenue Growth (YoY)
-92.8%
Gross Margin
-73.2%
Operating Margin
-1,304.0%
Net Margin
+88.1%
EPS Growth
-92.8%
Financial Health
Cash/Price Ratio
+41.2%
Current Ratio
2.6x
Debt/Equity
1,178.2x
ROE
-196.4%
ROA
-38.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Regenxbio Inc. (RGNX) Business Model
About Regenxbio Inc.
What They Do
Develops gene therapies for genetic disorders.
Business Model
Regenxbio Inc. operates by developing and commercializing gene therapies utilizing its NAV Technology Platform. The company generates revenue through licensing its proprietary AAV vectors to partners and earns royalties from approved products like Zolgensma, which supports its advancements in treating various genetic disorders.
Additional Information
Founded in 2009 and based in Rockville, Maryland, Regenxbio Inc. focuses on a diverse pipeline targeting retinal diseases, neuromuscular disorders, and neurodegenerative conditions, positioning itself as a leader in the gene therapy sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
353
CEO
Mr. Curran M. Simpson M.S.
Country
United States
IPO Year
2015
Website
www.regenxbio.comRegenxbio Inc. (RGNX) Latest News & Analysis
Latest News
REGENXBIO Inc. (RGNX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
24 days ago
Quick Summary
REGENXBIO Inc. (RGNX) presented at the RBC Capital Markets Global Healthcare Conference, discussing key developments and future plans.
Why It Matters
REGENXBIO's presentation at a major healthcare conference could signal strategic developments, potential partnerships, or advancements in technology, influencing stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
REGENXBIO Inc. (Nasdaq: RGNX) will participate in two investor conferences: RBC Capital Markets on May 20 and Stifel's Virtual Ophthalmology Forum on May 26. Webcasts available online.
Why It Matters
REGENXBIO's participation in key investor conferences highlights its engagement with the investment community, potentially impacting stock visibility and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Regenxbio reported that its experimental therapy for a muscle-wasting disorder achieved primary endpoints in a late-stage clinical trial.
Why It Matters
Positive results in a late-stage study boost Regenxbio's potential to gain market approval, likely enhancing its stock value and attracting investor interest in its growth prospects.
Source: Reuters
Market Sentiment:
Positive
Quick Summary
REGENXBIO Inc. (RGNX) held its Q1 2026 earnings call, detailing financial performance and updates on product development. Further specifics can be found in the full transcript.
Why It Matters
The Q1 2026 earnings call for REGENXBIO Inc. provides insights into financial performance, growth prospects, and market positioning, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The company reported positive Phase III results for RGX-202, achieving its primary endpoint. RGX-121's clinical hold has been lifted, and key developments in diabetic retinopathy and wet AMD are anticipated.
Why It Matters
Positive Phase III results for RGX-202 boost confidence in the company's pipeline, potentially increasing stock value and attracting investor interest. Upcoming data releases may further impact market perception.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
REGENXBIO Inc. (NASDAQ:RGNX) announced topline and interim data from the Phase 1/2/3 AFFINITY DUCHENNE trial for its gene therapy RGX-202 targeting Duchenne muscular dystrophy.
Why It Matters
REGENXBIO's trial results for RGX-202 could impact stock valuation and market sentiment, influencing investor confidence in the company's future growth and potential revenue from gene therapies.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About RGNX Stock
What is Regenxbio Inc.'s (RGNX) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Regenxbio Inc. (RGNX) has a median price target of $19.00. The highest price target is $50.00 and the lowest is $10.00.
Is RGNX stock a good investment in 2026?
According to current analyst ratings, RGNX has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.07. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RGNX stock?
Wall Street analysts predict RGNX stock could reach $19.00 in the next 12 months. This represents a 168.7% increase from the current price of $7.07. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Regenxbio Inc.'s business model?
Regenxbio Inc. operates by developing and commercializing gene therapies utilizing its NAV Technology Platform. The company generates revenue through licensing its proprietary AAV vectors to partners and earns royalties from approved products like Zolgensma, which supports its advancements in treating various genetic disorders.
What is the highest forecasted price for RGNX Regenxbio Inc.?
The highest price target for RGNX is $50.00 from at , which represents a 607.2% increase from the current price of $7.07.
What is the lowest forecasted price for RGNX Regenxbio Inc.?
The lowest price target for RGNX is $10.00 from at , which represents a 41.4% increase from the current price of $7.07.
What is the overall RGNX consensus from analysts for Regenxbio Inc.?
The overall analyst consensus for RGNX is bullish. Out of 5 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $19.00.
How accurate are RGNX stock price projections?
Stock price projections, including those for Regenxbio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 1:26 PM UTC